| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Testosterone and hormone clinic or telehealth website |
| Population | Men |
| Source | Maze Men's Health |
| URL | mazemenshealth.com/blog/can-glp-1s-raise-testosterone-what-men-taking-ozempic-wegovy-or-zepbound-should-know (opens in a new tab) |
Specific Claim Evaluated
Some men with obesity and low testosterone may see testosterone improve on GLP-1 receptor agonists, mainly through weight and metabolic improvement rather than a direct effect, and weight loss is first-line for obesity-associated hypogonadism.
Primary Research Supporting or Contradicting the Claim
A meta-analysis of 7 studies found that GLP-1 receptor agonists increased total testosterone in overweight and obese men, with the increase correlated with weight loss, and that a direct testicular action could not be demonstrated (Salvio et al., 2025).
Corrected Evidence-Based Interpretation
The article is correct. Testosterone gains with GLP-1 receptor agonists are modest and do not replace diagnostic evaluation for hypogonadism.
Rationale for Grade
The article avoids describing the drugs as testosterone boosters, distinguishes GLP-1 therapy from testosterone replacement and notes possible lean mass loss. Its claims are consistent with meta-analytic evidence.
References
- Salvio G, Ciarloni A, Ambo N, Bordoni M, Perrone M, Rossi S, Balercia G. Effects of glucagon-like peptide 1 receptor agonists on testicular dysfunction: a systematic review and meta-analysis. Andrology. 2025;13(8):2022-2034. PMID
Supporting excerpt: "The limitations of the current literature do not allow to demonstrate a direct action"